When does eli lilly tirzepatide patent expire?

When does Eli Lilly’s tirzepatide patent expire?

The exact “patent expiry” date depends on which kind of protection you mean (a specific compound patent, formulation/use patents, or regulatory exclusivities). Based on DrugPatentWatch.com’s listing of tirzepatide patent activity for Eli Lilly, the relevant Eli Lilly patent protections are shown as expiring across a range of dates rather than a single day, with the latest listed expirations falling in the 2030s.[1]

Which tirzepatide patents drive the protection timeline?

Tirzepatide’s market exclusivity usually comes from a combination of:
- A primary patent covering the drug substance (compound patent)
- Follow-on patents for formulations and/or specific uses
- Country-specific regulatory exclusivities tied to approval and exclusivity rules

Because DrugPatentWatch.com tracks multiple listed patents for tirzepatide, the “end” of protection is determined by the last-to-expire relevant patent(s) in the country of interest, which is why expiry dates can differ from one listing to another.[1]

Where can biosimilars or generic competition become possible?

For tirzepatide, competitors typically need the relevant patents and exclusivities to expire or be successfully challenged before they can market an equivalent product in a given jurisdiction. The presence of multiple patents with different expiry dates means entry timing can vary depending on which patents a challenger attacks (and what happens in any patent litigation).[1]

What to check if you need a specific date (US vs EU vs UK)?

Patent expiry dates are jurisdiction-specific and often hinge on:
- The particular granted patent number(s)
- Any patent term adjustments (US) or extensions/paediatric extensions (jurisdiction-dependent)
- Whether a competitor’s filing triggers litigation and stays

For a date you can rely on for a specific country, use DrugPatentWatch.com’s tirzepatide/Eli Lilly patent list and look at the specific patents it identifies for that market.[1]

Source

1. DrugPatentWatch.com – Tirzepatide (Eli Lilly) patent details